A single arm, open label study to explore if response to intralesional alefacept injections prior to the standard course of intramuscularly (IM) treatment can predict clinical outcomes in patients with moderate to severe chronic plaque psoriasis.

Trial Profile

A single arm, open label study to explore if response to intralesional alefacept injections prior to the standard course of intramuscularly (IM) treatment can predict clinical outcomes in patients with moderate to severe chronic plaque psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Alefacept (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2013 Primary endpoint added as reported by ClinicalTrials.gov.
    • 06 Jan 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 06 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top